Marchex Raises Q2 Guidance, Reports Improved Q1 Results, and Details Archenia Acquisition

summarizeSummary

Marchex reported improved Q1 2026 financial results and significantly raised its Q2 2026 Adjusted EBITDA guidance, while also providing a positive outlook for the rest of the year and further details on its strategic acquisition of Archenia.

check_boxKey Events

• Improved Q1 2026 Financial Results

  Marchex reported GAAP revenue of $10.6 million, with a reduced net loss of $1.7 million and an Adjusted EBITDA loss of $0.1 million, which would be a $0.6 million gain excluding reorganization and acquisition costs.

• Raised Q2 2026 Guidance

  The company anticipates sequential revenue increase and raised its Adjusted EBITDA guidance for Q2 2026 to a range of $1.6 to $1.8 million, up from prior guidance of over $1 million.

• Strong Future Outlook

  Marchex projects sequential revenue increases and potential acceleration into Q3 2026, with stand-alone Adjusted EBITDA of $2 million or more, and combined Adjusted EBITDA of $2.5 million or more (annualized run rate of $10 million+) if the Archenia acquisition closes.

• Archenia Acquisition Update

  Marchex confirmed entering a Stock Purchase Agreement to acquire Archenia, approved by a Special Committee due to related parties, and subject to disinterested stockholder approval, with an expected closing in July 2026.

auto_awesomeAnalysis

This filing is very important because Marchex reported improved Q1 financial results and significantly raised its Adjusted EBITDA guidance for Q2 2026, indicating a positive shift in its financial trajectory. The company also provided a strong outlook for Q3 and the full year, driven by new AI-based product adoption and the strategic acquisition of Archenia. The detailed update on the Archenia transaction, including the Special Committee's approval due to related parties and the requirement for disinterested stockholder approval, provides crucial governance context for this growth-driving acquisition.